

# Relationship between Hemolysis and Resistance to Antibiotics among Clinical Isolates of *Escherichia Coli* from Urine

Moamen Al Zoubi<sup>1\*</sup>, Megan Farrington<sup>2</sup>, and Steven Hatch<sup>1</sup>

<sup>1</sup>University of Massachusetts Memorial Medical Center, Worcester, MA, USA

<sup>2</sup>Quest Diagnostics, Microbiology Supervisor, USA

\*Corresponding author: Al Zoubi M, University of Massachusetts Memorial Medical Center, Worcester, MA, USA, E-mail: moamen.alzoubi@gmail.com

Received: 01 Jun, 2020 | Accepted: 28 Aug, 2020 | Published: 08 Sep, 2020

**Citation:** Al Zoubi M, Farrington M, Hatch S (2020) Relationship between Hemolysis and Resistance to Antibiotics among Clinical Isolates of *Escherichia Coli* from Urine. Clin Res Open Access 6(2): dx.doi.org/10.16966/2469-6714.159

**Copyright:** © 2020 Al Zoubi M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

*E. coli* is responsible for many community-onset and nosocomial infections. The increasingly high level of antimicrobial drug resistance prevalence is a worsening problem. *E. coli* has many resistance mechanisms. In some cases, these mechanisms confer additional virulence of the pathogen. *E. coli* can produce several types of hemolysin, including an extracellular protein ( $\alpha$ -hemolysin), a cell-bound protein ( $\beta$ -haemolysin) and a hemolysin expressed by nalidixic acid-resistant mutants ( $\gamma$ -hemolysin).  $\alpha$ -Hemolysin is a virulence factor in strains causing different extra-intestinal infections [1]. It can induce osmotic lysis of erythrocytes due to its pore-forming activity, and is cytotoxic to several types of human cell [2]. This study was undertaken to evaluate the relationship between hemolysin production and resistance to antibiotics among clinical isolates of *E. coli* from urine.

**Keywords:** Antimicrobial stewardship

## Methods

We reviewed 1792 *E. coli* isolates in urine cultures from UMASS Memorial Medical Center between November 2017 to April 2018. These isolates were either hemolytic strain (HEC) or non-hemolytic strain (NHEC). Hemolysis was identified by comparing the growth characteristics and colony morphology seen on TSA II with 5% sheep blood/MacConkey agar of lactose-fermenting, non-mucoid, gram negative colonies. HEC produce a zone of beta-hemolysis that is visible on TSA II agar. Further biochemical testing was performed to confirm the identification of *E. coli*. The percentage of antibiotics resistance was compared between two groups. The Vitek system uses an extended-spectrum  $\beta$ -lactamase (ESBL) screening well and compares the resistance pattern using phenotypic software to determine if the isolate is ESBL. The screening well contains cefepime, ceftazidime, and cefotaxime, with and without clavulanic acid, to determine positive and negative. The results were logged as ESBL-positive or ESBL-negative. We matched 110 ESBL *E. coli* isolates to 110 non-ESBL *E. coli* isolates, and antibiotic susceptibility was compared. The statistical significance of differences in resistance to antimicrobial agents between hemolytic and non-hemolytic isolates was tested using the chi-square test or Fisher's exact test, when expected cell sizes were less than 5. Differences were considered significant when  $P$  was  $<0.05$ .

## Results

Among all *E. coli* isolates, 479 (26.7%) were HEC while 1313 (73.2%)

isolate were NHEC. The percentage of ESBL isolates among both groups was the same (6%). NHEC isolates were more likely to be resistant to fluoroquinolones when compared to HEC (10 % vs 4%  $P=0.0004$  for ciprofloxacin: 5.8 % vs 0.8%  $P=0.0001$  for levofloxacin). NHEC isolates were also more likely to be resistant to cefepime when compared to HEC (2.7 % vs. 0.9%  $P=0.02$ ) (Table 1). There was no significant difference among other antibiotics between two groups. Among the ESBL group, 83 isolates (75.5%) were NHEC while 27 (24.5%) were HEC. The percentage of resistance to antibiotics was not statistically significant between the two groups (Table 2). Among the non-ESBL *E. coli* isolates, 73 (66.4%) were NHEC while 37 (33.6%) were HEC. Similarly, the percentage of resistance to antibiotics was not significantly different between the two groups (Table 3).

## Conclusion

The percentages of isolates with resistance to both levofloxacin ciprofloxacin, cefepime but not to other agents, were significantly higher ( $P < 0.05$ ) among NHEC isolates than among HEC isolates. Although fluoroquinolone use is now discouraged, this finding may represent a narrow indication for its use in certain clinical scenarios [3-6].

## Disclosures

All authors: No reported disclosures.

**Table 1:** Antibiotics Resistance (% Resistance).

Antibiotics	Hemolytic E.Coli (N:479)	Non-Hemolytic E.Coli (N:1313)	p Value
Ciprofloxacin	4%	10%	0.0004
Levofloxacin	0.8%	5.8%	0.0001
Cefepime	2.7%	0.9%	0.02
Piperacillin/ tazobactam	1%	0.1%	0.93
Amikacin	0.2%	0.00%	0.16
Ceftazidime	2%	1.5%	0.48
Positive ESBL	6%	6%	0.65

**Table 2:** Antibiotics Resistance among ESBL isolates (% Resistance).

Antibiotics	ESBL Hemolytic E.Coli (N:27)	ESBL Non-Hemolytic E.Coli (N:83)	p Value
Ciprofloxacin	59.20%	66.20%	0.57
Levofloxacin	55.4%	51.80%	0.36
Cefepime	48.10%	32.50%	0.2
Piperacillin/ tazobactam	25.9%	16.80%	0.37
Ceftazidime	37.00%	26.50%	0.36
Amikacin	0.0%	0.00%	0.99
Positive blood culture	3.7%	7.20%	0.99

**Table 3:** Antibiotics Resistance among non ESBL isolates (% Resistance).

Antibiotics	Hemolytic E.Coli (N:37)	Non-Hemolytic E.Coli (N:73)	p Value
Ciprofloxacin	5.40%	11%	0.35
Levofloxacin	2.70%	8.30%	0.42
Cefepime	0.00%	0.00%	0.99
Piperacillin/ tazobactam	2.70%	2.70%	0.99
Ceftazidime	0.00%	2.70%	0.55
Amikacin	0.00%	1.30%	0.99

## References

- Cavaliere, SJ, Bohach, GA, Snyder IS (1984) *Escherichia coli*  $\alpha$ -hemolysin: characteristics and probable role in pathogenicity. *Microbiological Reviews* 48: 326-343.
- Walton JR, Smith DH (1969) New hemolysin ( $\gamma$ ) produced by *Escherichia coli*. *J Bacteriol* 98: 304-305.
- Šišková P, Černohorská L, Mahelová M, Turková K, Woznicová V (2015) Phenotypes of *Escherichia coli* isolated from urine: Differences between extended-spectrum  $\beta$ -lactamase producers and sensitive strains. *J Microbiol Immunol Infect* 48: 329-334.
- Sharma S, Bhat GK, Shenoy S (2007) Virulence factors and drug resistance in *Escherichia coli* isolated from extraintestinal infections. *Indian J Med Microbiol* 25: 369-373.
- Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR (2016) Fluoroquinolone-Resistant and Extended-Spectrum  $\beta$ -Lactamase-Producing *Escherichia coli* Infections in Patients with Pyelonephritis, United States(1). *Emerg Infect Dis* 22: 1594-1603.
- Luis Martínez-Martínez, Felipe Fernández, Evelio J Perea, (1999) Relationship between haemolysis production and resistance to fluoroquinolones among clinical isolates of *Escherichia coli*, *Journal of Antimicrobial Chemotherapy* 43: 277-279.